EUR USD GBP
+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Synta Pharmaceuticals Corp. (SNTA) - Financial and Strategic SWOT Analysis Review

  • ID: 1322625
  • SWOT Analysis
  • May 2016
  • 49 pages
  • GlobalData
1 of 4

FEATURED COMPANIES

  • Amgen Inc.
  • Cerulean Pharma, Inc.
  • Immunomedics, Inc.
  • Infinity Pharmaceut
  • Intezyne, Inc
  • Mirati Therapeutics Inc.
  • MORE
Synta Pharmaceuticals Corp. (SNTA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Synta Pharmaceuticals Corp. (Synta) is a pharmaceutical company that discovers, develops and commercializes novel pharmaceutical products for the treatment of cancer and other severe medical conditions. It has a unique chemical compound, an integrated discovery engine and a diverse pipeline of clinical and preclinical stage drug candidates. The company has a clinical-stage drug candidate (ganetespib) in cancer and a novel, proprietary small molecule cancer drug development program, the HDC program. Ganetespib is a novel, potent, small molecule inhibitor of Hsp90, a molecular chaperone required for the proper folding and activation of various cancer-promoting proteins. Synta is headquartered in Lexington, Massachusetts, the US.

Synta Pharmaceuticals Corp. Key Recent Developments

Nov 05, 2015: Synta Reports Third Quarter 2015 Financial Results
Sep 09, 2015: Synta Names Alan C. Rigby, Ph.D. Chief Scientific Officer
Aug 06, 2015: Synta Reports Second Quarter 2015 Financial Results
May 07, 2015: Synta Reports First Quarter 2015 Financial Results
Apr 27, 2015: Synta Announces Chen Schor Named President, Chief Executive Officer and Director

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Amgen Inc.
  • Cerulean Pharma, Inc.
  • Immunomedics, Inc.
  • Infinity Pharmaceut
  • Intezyne, Inc
  • Mirati Therapeutics Inc.
  • MORE
List of Tables

List of Figures

Section 1 - About the Company

Synta Pharmaceuticals Corp. - Key Facts

Synta Pharmaceuticals Corp. - Key Employees

Synta Pharmaceuticals Corp. - Key Employee Biographies

Synta Pharmaceuticals Corp. - Major Products and Services

Synta Pharmaceuticals Corp. - Pharmaceutical Pipeline Products Data

Synta Pharmaceuticals Corp., Pipeline Products by Therapy Area

Synta Pharmaceuticals Corp., Pipeline Products by Development Phase

Synta Pharmaceuticals Corp. - History

Synta Pharmaceuticals Corp. - Company Statement

Synta Pharmaceuticals Corp. - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2 – Company Analysis

Synta Pharmaceuticals Corp. - Business Description

Synta Pharmaceuticals Corp. - Corporate Strategy

Synta Pharmaceuticals Corp. - SWOT Analysis

SWOT Analysis - Overview

Synta Pharmaceuticals Corp. - Strengths

Strength - Research and Development Activities

Strength - Proprietary Technology Platform

Synta Pharmaceuticals Corp. - Weaknesses

Weakness - History of losses

Weakness - Product Discontinuations

Synta Pharmaceuticals Corp. - Opportunities

Opportunity - Pipeline of Cancer Products

Opportunity - Market Potential: Cancer

Opportunity - Merger Agreement with Madrigal

Synta Pharmaceuticals Corp. - Threats

Threat - Intense Competition

Threat - Reliance on Third Parties

Threat - Stringent Government Regulations

Synta Pharmaceuticals Corp. - Key Competitors

Section 3 – Company Financial Ratios

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

Section 4 – Company’s Lifesciences Financial Deals and Alliances

Synta Pharmaceuticals Corp., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016

Synta Pharmaceuticals Corp., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016

Synta Pharmaceuticals Corp., Recent Deals Summary

Section 5 – Company’s Recent Developments

Nov 05, 2015: Synta Reports Third Quarter 2015 Financial Results

Sep 09, 2015: Synta Names Alan C. Rigby, Ph.D. Chief Scientific Officer

Aug 06, 2015: Synta Reports Second Quarter 2015 Financial Results

May 07, 2015: Synta Reports First Quarter 2015 Financial Results

Apr 27, 2015: Synta Announces Chen Schor Named President, Chief Executive Officer and Director

Mar 12, 2015: Synta Reports Fourth Quarter and Year-End 2014 Financial Results

Feb 05, 2015: Synta Outlines New Corporate Strategy

Section 6 – Appendix

Methodology

Ratio Definitions

About us

Contact Us

Disclaimer

List of Tables

Synta Pharmaceuticals Corp., Key Facts

Synta Pharmaceuticals Corp., Key Employees

Synta Pharmaceuticals Corp., Key Employee Biographies

Synta Pharmaceuticals Corp., Major Products and Services

Synta Pharmaceuticals Corp., Number of Pipeline Products by Therapy Area

Synta Pharmaceuticals Corp., Number of Pipeline Products by Development Stage

Synta Pharmaceuticals Corp., Pipeline Products By Therapy Area and Development Phase

Synta Pharmaceuticals Corp., History

Synta Pharmaceuticals Corp., Other Locations

Synta Pharmaceuticals Corp., Subsidiaries

Synta Pharmaceuticals Corp., Key Competitors

Synta Pharmaceuticals Corp., Ratios based on current share price

Synta Pharmaceuticals Corp., Annual Ratios

Synta Pharmaceuticals Corp., Interim Ratios

Synta Pharmaceuticals Corp., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016

Synta Pharmaceuticals Corp., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016

Synta Pharmaceuticals Corp., Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

List of Figures

Synta Pharmaceuticals Corp., Pipeline Products by Therapy Area

Synta Pharmaceuticals Corp., Pipeline Products by Development Phase

Synta Pharmaceuticals Corp., Performance Chart (2011 - 2015)

Synta Pharmaceuticals Corp., Ratio Charts

Synta Pharmaceuticals Corp., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016

Synta Pharmaceuticals Corp., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016
Note: Product cover images may vary from those shown
3 of 4
ProLynx LLC
Nippon Kayaku Co., Ltd.
Nektar Therapeutics
Merrimack Pharmaceuticals, Inc.
Intezyne, Inc
Immunomedics, Inc.
Cerulean Pharma, Inc.
Mirati Therapeutics Inc.
Immune Pharmaceuticals, Inc.
Astex Pharmaceuticals, Inc.
Amgen Inc.
Infinity Pharmaceut
Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll